ESEV R&D Competitors

CILCARE is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. We believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases. CILCARE External Innovation supports its partners in the health and life-sciences sector in the development of new therapies to prevent and treat auditory-related diseases including inherited hearing loss, synaptopathy, ototoxicity, sensorineural hearing loss and tinnitus. CILCARE Therapeutics has forged a portfolio of proprietary drug candidates and co-developed programs, while pioneering an unprecedented clinical approach to developing compounds targeting cochlear synaptopathy. CILCARE Auditory Analytics aims to position hearing as a key asset of preventive medicine and global healthcare monitoring. We aim to utilize patients' auditory measurements to define digital auditory signatures that will serve to characterize different forms of hearing impairments or other pathologies with precision.

About Clintrex Research Corporation (www.clintrex.com) Clintrex Research Corporation (CLINTREX) is a clinical research organization that works with pharmaceutical and biotech companies to design clinical trials, operationalize development plans, and develop regulatory pathways for new treatments for CNS diseases. CLINTREX incorporates an integrated team of internationally renowned experts with disease-specific knowledge to identify, clarify, and solve preclinical, clinical trial, biostatistical, and regulatory issues essential to product development and approval.

4P Therapeutics develops new transdermal products that meet the needs of patients, physicians, and payers. 4P Therapeutics is a product research and development company with expertise in technology development, drug formulation, product design, and preclinical & clinical development. 4P is not dependent on a specific platform technology but instead evaluates multiple different transdermal technology and formulation approaches to find the right match for a particular drug or biologic product being developed. Our in-house capabilities allow us to work with proven preclinical models either in vitro or in vivo and have the capability to move quickly to the clinic with a technology and formulation tailored for each specific transdermal product. We believe that the keys to success in the novel transdermal space are having the freedom to choose from multiple technologies and not be burdened with a one-size-fits-all platform technology as well as having world-class experience in transdermal formulation and product development. Current industry dynamics for transdermal product development and commercialization have lead us to create a business model for 4P that takes advantage of our own proprietary technology as well as the freedom to operate with multiple technologies. 4P has built an infrastructure that allows our experienced team to go from concept to proof-of-concept in humans in our Atlanta, GA, facility. The 4P Therapeutics team is experienced in developing a broad range of drug deliver technologies, particularly novel transdermal technologies for compounds that are currently injected or administered by SC or IV infusion. The company's team also offers experience with developing vaccines, medical devices, and diagnostics.